ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
21 hedge funds and large institutions have $14.6M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
40% more capital invested
Capital invested by funds: $10.4M → $14.6M (+$4.2M)
17% more funds holding
Funds holding: 18 → 21 (+3)
0.45% more ownership
Funds ownership: 33.25% → 33.7% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.13M |
| 2 |
LWPC
Legacy Wealth Partners (California)
Calabasas,
California
|
+$243K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$52.9K |
| 4 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$7.05K |
| 5 |
JWA
JFS Wealth Advisors
Hermitage,
Pennsylvania
|
+$4.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$808K |
| 2 |
Morgan Stanley
New York
|
-$156K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$79.1K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$76.8K |
| 5 |
Citigroup
New York
|
-$41.1K |
CNCR Hedge Fund Activity: Q2 2020 in Review
21 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2020, worth a combined $14.6M — up 40% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNCR positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 10 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $1.13M. The largest seller was Susquehanna International Group, cutting an estimated $808K.
- 21 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2020, up from 18 in Q1 2020.
- Funds reported $14.6M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2020, up 40% quarter-over-quarter.
- 5 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2020 and 2 closed out, a net change of +3 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2020 was Jane Street, an estimated $1.13M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2020 was Susquehanna International Group, an estimated $808K sold.
Based on aggregated 13F filings for Q2 2020.